Brief: Erytech Announces Trybeca-1 Phase 3 Trial In 2L Pancreatic Cancer To Continue To Final Analysis

Phaxiam Therapeutics SA

08/02/2021 06:37

Feb 8 (Reuters) - Erytech Pharma SA  ERYP.PA :
    * ERYTECH ANNOUNCES TRYBECA-1 PHASE 3 TRIAL  IN 2L
PANCREATIC
CANCER TO CONTINUE TO FINAL ANALYSIS
    * INDEPENDENT DATA MONITORING COMMITTEE (IDMC) RECOMMENDS
TRIAL TO
CONTINUE TO FINAL ANALYSIS, EXPECTED IN Q4 2021
    * NO SAFETY ISSUES IDENTIFIED, CONSISTENT WITH OBSERVATIONS
IN
PREVIOUS IDMC REVIEWS

Source text for Eikon:  ID:nGNE9tRWzs 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))